Last reviewed · How we verify
Prednisone - Azathioprine
At a glance
| Generic name | Prednisone - Azathioprine |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease (PHASE3)
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) (PHASE3)
- TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
- Determination of the Optimal Treatment Target in Ulcerative Colitis (PHASE4)
- Different Immunosuppressive Treatment in iMN (PHASE3)
- BDB-001 Phase III Trial in ANCA-Associated Vasculitis (PHASE3)
- Efficacy Study of Two Treatments in the Remission of Vasculitis (PHASE3)
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone - Azathioprine CI brief — competitive landscape report
- Prednisone - Azathioprine updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI